The ocular renin-angiotensin system: a therapeutic target for the treatment of ocular disease

Michael J Giese1, Robert C Speth2

  • 14148 NW 19th Terrace, Oakland Park FL 33309, United States.

Pharmacology & Therapeutics
|November 30, 2013
PubMed

Insights

The eye has a local renin-angiotensin system (RAS) that impacts ocular health. Dysregulation of this system may contribute to eye diseases, offering new therapeutic targets.

Area of Science:

  • Ocular physiology and pharmacology
  • Cardiovascular research

Background:

  • The renin-angiotensin system (RAS) regulates blood pressure and fluid balance.
  • RAS dysregulation is linked to cardiovascular diseases, making it a drug target.
  • Local RASs exist in various organs, including the eye.

Purpose of the Study:

  • To review the evidence for a local RAS in the eye.
  • To discuss the role of ocular RAS in eye diseases.
  • To explore pharmacological targeting of the ocular RAS for novel therapies.

Main Methods:

  • Literature review of studies on RAS components in ocular tissues.
  • Analysis of the functional significance of local RAS in ocular disease.
  • Discussion of systemic RAS dysregulation's impact on eye conditions.

Main Results:

  • Components of the RAS are present in multiple ocular structures.
  • Local ocular RAS plays a functional role in eye health and disease.
  • Systemic RAS dysregulation affects ocular disease pathogenesis.

Conclusions:

  • The eye possesses a local RAS with functional significance.
  • Ocular RAS dysregulation is implicated in eye diseases.
  • Targeting the ocular RAS presents potential therapeutic strategies for eye conditions.

Related Concept Videos

Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K